Literature DB >> 15540210

Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: implications for tobacco smoking during adolescence.

Carmen J Marsit1, Duk-Hwan Kim, Mei Liu, Philip W Hinds, John K Wiencke, Heather H Nelson, Karl T Kelsey.   

Abstract

The putative tumor suppressors RASSF1A and BLU are mapped adjacent to one another on chromosome 3p21.3, a region frequently deleted in lung cancer. These genes are often inactivated by promoter hypermethylation, but the association of this inactivation with clinical features of the disease or with carcinogen exposure has been poorly studied. Early age starting smoking has been hypothesized as an independent risk factor for lung cancer, and mechanistically, adolescence may constitute a critical period for tobacco carcinogen exposure. To study the relationship of tobacco smoke exposure with hypermethylation of RASSF1A and BLU, methylation-specific PCR was performed on a case series study of incident, surgically resected non-small cell lung cancer (NSCLC), and the prevalence of this alteration was examined in relation to clinical and exposure information collected on the patients. Hypermethylation of the RASSF1A promoter occurred in 47% (83/178) and of the BLU promoter in 43% (68/160) of NSCLC tumors examined. There was no significant association between methylation of these 2 genes, but methylation of either of these genes tended to occur more often in the adenocarcinoma (AC) histology compared to squamous cell carcinoma (SCC). Controlling for pack-years smoked, age, gender and histology, starting smoking under age 18 was significantly related to RASSF1A methylation [prevalence ratio (PR) = 1.6, 95% confidence interval [CI] = 1.1-2.3]. These results indicate that starting smoking under age 18 is an independent risk for RASSF1A hypermethylation, thus identifying a molecular alteration related to the epidemiologic effect of teenage smoking as a lung cancer risk. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15540210     DOI: 10.1002/ijc.20714

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma.

Authors:  Milica Kontic; Jelena Stojsic; Dragana Jovanovic; Vera Bunjevacki; Simona Ognjanovic; Jacquelyn Kuriger; Susan Puumala; Heather H Nelson
Journal:  Clin Lung Cancer       Date:  2011-12-13       Impact factor: 4.785

2.  Loss of heterozygosity and methylation of multiple tumor suppressor genes on chromosome 3 in hepatocellular carcinoma.

Authors:  Xiaoying Zhang; Hiu Ming Li; Zhiyan Liu; Gengyin Zhou; Qinghui Zhang; Tingguo Zhang; Jianping Zhang; Cuijuan Zhang
Journal:  J Gastroenterol       Date:  2012-07-06       Impact factor: 7.527

3.  Association of cigarette smoking and CRP levels with DNA methylation in α-1 antitrypsin deficiency.

Authors:  Mateusz Siedlinski; Barbara Klanderman; Robert A Sandhaus; Alan F Barker; Mark L Brantly; Edward Eden; N Gerard McElvaney; Stephen I Rennard; James M Stocks; James K Stoller; Charlie Strange; Gerard M Turino; Edward J Campbell; Dawn L Demeo
Journal:  Epigenetics       Date:  2012-07-01       Impact factor: 4.528

Review 4.  Second-hand smoke and human lung cancer.

Authors:  Ahmad Besaratinia; Gerd P Pfeifer
Journal:  Lancet Oncol       Date:  2008-07       Impact factor: 41.316

5.  Linking epidemiology to epigenomics--where are we today?

Authors:  Cornelia M Ulrich; William M Grady
Journal:  Cancer Prev Res (Phila)       Date:  2010-12

6.  MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index.

Authors:  Scott M Langevin; Roslyn A Stone; Clareann H Bunker; Jennifer R Grandis; Robert W Sobol; Emanuela Taioli
Journal:  Carcinogenesis       Date:  2010-03-02       Impact factor: 4.944

7.  Key epigenetic changes associated with lung cancer development: results from dense methylation array profiling.

Authors:  Heather H Nelson; Carmen J Marsit; Brock C Christensen; E Andres Houseman; Milica Kontic; Joseph L Wiemels; Margaret R Karagas; Margaret R Wrensch; Shichun Zheng; John K Wiencke; Karl T Kelsey
Journal:  Epigenetics       Date:  2012-06-01       Impact factor: 4.528

8.  Genetic and epigenetic tumor suppressor gene silencing are distinct molecular phenotypes driven by growth promoting mutations in nonsmall cell lung cancer.

Authors:  Carmen J Marsit; E Andres Houseman; Heather H Nelson; Karl T Kelsey
Journal:  J Cancer Epidemiol       Date:  2009-01-28

9.  Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles.

Authors:  Brock C Christensen; Carmen J Marsit; E Andres Houseman; John J Godleski; Jennifer L Longacker; Shichun Zheng; Ru-Fang Yeh; Margaret R Wrensch; Joseph L Wiemels; Margaret R Karagas; Raphael Bueno; David J Sugarbaker; Heather H Nelson; John K Wiencke; Karl T Kelsey
Journal:  Cancer Res       Date:  2009-07-28       Impact factor: 12.701

10.  RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China.

Authors:  Qiang Lin; Junfeng Geng; Kelong Ma; Jian Yu; Jinfeng Sun; Zhenya Shen; Guoliang Bao; Yinming Chen; Hongyu Zhang; Yinghua He; Xiaoying Luo; Xu Feng; Jingde Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-09       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.